NCT04789408CompletedPhase 1
Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia
Source: EU CTIS (euclinicaltrials.eu) · Last updated 2 Jul 2024
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 22 Aug 2023
- Start date
- 8 Nov 2022
- Lead sponsor
- Kite Pharma Inc.
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT04789408
- EU CT number
- 2023-507748-35-00
- EudraCT number
- 2020-000962-40
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 10
- 4 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitaetsklinikum Frankfurt AöR Coordinator of this site? Confirm its status | Frankfurt Am Main | Germany | Completed |
| Universitaetsklinikum Ulm AoR Coordinator of this site? Confirm its status | Ulm | Germany | Completed |
| Institut Paoli-Calmettes Coordinator of this site? Confirm its status | Marseille | France | Completed |
| Institut Universitaire Du Cancer Toulouse-Oncopole Coordinator of this site? Confirm its status | Toulouse Cedex 9 | France | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.